Atypical Fibroxanthoma (AFX) is a rare cutaneous mesenchymal neoplasm, predominantly found on sun-damaged skin of the head and neck in elderly patients. But uncommonly it can develop on a burn scar with or without actinic damage. Malignancy development is the major complication of severe burns and malignant transformations of those burn scars are accepted as Marjolin’s ulcers clinically. The most common malignancy in this setting is Squamous Cell Carcinoma (SCC), followed by Basal Cell Carcinoma (BCC) and Malignant Melanoma (MM). Mesenchymal tumors especially malign forms quite infrequently seen on scar tissue. Herein, we present a rare and unusual case of AFX arising on the non-sun-damaged area within a chronic burn scar of a young patient. Four cases of burn-related AFX reported in the literature are reviewed and the histopathological features and differential diagnosis are discussed.

Keywords: Actinic damage; Marjolin's ulcer; Non-sun-damaged skin

Introduction

Atypical Fibroxanthoma (AFX) is an uncommon, low-grade sarcoma, characterized by morphologic features of malignancy but indolent clinical behavior. AFX mainly affects elderly males in the seventh decade [1,2].

Presentation at a younger age is exceptional but may be seen in the setting of Xeroderma Pigmentosum or Li Fraumeni syndrome [3,4]. Malignant transformation of untreated chronic wounds is a well-known issue. Beside the common tumors are SCC, BCC, and MM, there are also other tumors such as sarcomas [5]. AFX is very rare in this setting and there have been only four previous reports of AFX in chronic burn scar to the best of our knowledge.

Here, we present a case of AFX arising in a chronic burn scar without associated actinic damage and review the literature.

Case Report

A 31-year-old male patient with a history of a thermal burn 20 years ago, admitted to plastic surgery service in Medipol Mega Hospital with the complaint of an intractable ulcer on his left side of mid-back despite conservative treatment for 6 months. On physical examination, there was an extensive burn scar affecting his entire back. On the scar area two exophytic nodular lesions were seen with erythematous scaly appearance, 1.3 cm and 0.5 cm in size with 0.2 cm distance in between (Figure 1). The surrounding skin showed mild contracture. Wide excision and split-thickness skin graft were performed with a clinical diagnosis of Marjolin’s ulcer.

Histologically both of nodular lesion had a relatively well-defined border in the dermis (Figure 2a). There was no epidermal connection or precursor lesion in the epidermis. The overlying epidermis was atrophic. Fibrosis due to the old burn scar in the surrounding skin was evident (Figure 2b). The tumor was composed of pleomorphic spindle cells, admixed with multinucleated osteoclast-like giant cells and mononuclear inflammatory cells including lymphocytes, plasma cells, and histiocytes. Hemorrhage was prominent in focal areas (Figure 2c). Mitosis was frequent and also had atypical and bizarre forms (Figure 2d). There was neither necrosis nor vascular, lymphatic or perineural invasion. Deep invasion into the subcutaneous fat was not observed. There was no evidence of epithelial or squamous differentiation. The
surgical resection margins were clear of the tumor. The immunohistochemical staining revealed strong positivity for CD68 and CD10 (Figure 3a and 3b). Neoplastic cells were negative with cytokeratin, p63, HMB45, Smooth Muscle Actin (SMA) and CD34. P53 expression was not seen, and Ki67 proliferation index was not very high (7-8%) (Figure 3c). On the basis of the pathological and immunohistochemical findings, a final diagnosis of atypical fibroxanthoma was given. In two years of clinical follow-up, no local recurrence or distant metastasis was observed.

Discussion

Atypical fibroxanthoma is rare in the general population and almost always occurs in severely sun damaged skin. The pathogenesis of AFX is still unclear, but most publications agree that ultraviolet-induced damage is an important factor in its development. For example, most lesions are found in the head and neck region, where exposure to sunlight is the highest [1,2,6].

Several factors have been described in the development of malignant tumors in the burn scars. These are chronic irritation and inflammation, potential carcinogens found in burnt skin, anoxia and abnormal immune surveillance resulting from damaged lymphatics and avascular tissue [5,7]. According to one of the proposed theories, the burn itself is not carcinogenic, but the tissue becomes more susceptible to other carcinogens such as ultraviolet radiation [8,9].

AFX frequently presents in the dermis as a well-circumscribed nodule with overlying epidermal collarette. Histologically, composed of a variable admixture of pleomorphic epithelioid, spindled, and multinucleated tumor giant cells with bizarre and pleomorphic nuclei. Mitotic activity is brisk and includes atypical forms [2,6]. Diagnosis requires extensive sampling and an expanded panel of immunohistochemistry. Markers such as CD68, CD10, vimentin, and SMA are not specific but are positive in the majority of tumoral cells [6]. The differential diagnosis includes a wide range of tumors having a spindle and sarcomatous features. Epithelial tumors (poorly differentiated SCC), melanocytic tumors (spindle cell MM) and sarcomas (cutaneous leiomyosarcoma, dermatofibrosarcoma protuberans, pleomorphic dermal sarcoma, angiosarcoma) should be excluded. For this reason, S-100, HMB-45, Melan-A (for MM), cytokeratins (for poorly differentiated carcinomas), SMA, desmin, H-caldesmon (for leiomyosarcomas), and CD31 (for angiosarcomas) should be used [6]. Main differential diagnosis is with Pleomorphic Dermal Sarcoma (PDS). Both are closely related cutaneous mesenchymal tumors which have same immunohistochemical expression pattern but have different clinicopathologic features. AFX does not show invasion of the deep subcutaneous tissue, and there are
no tumor necrosis, lymphovascular invasion or perineural infiltration. If these findings are present, the diagnosis should be PDS. It invades not only deep subcutaneous tissues but also frequently skeletal muscle and underlying fascia [1,2,6].

A comprehensive review of the reported four AFX cases arising in burn scar and current case are given in Table 1. Location of tumors was head and neck (three cases) and upper back (two cases). All patients were male. The age distribution was 31-93 (mean age: 61.2) and the current case was the youngest. The reported period between the injury and AFX detection was more than 40 years. In the current case, the latent period was about 20 years. Tumor size ranged between 1.3-4.2 cm (mean: 2.6 cm). In the follow-up, one patient had SCC and MM 10 years later [10], one patient’s information wasn’t available, in other cases metastasis and new cancer development has not been reported. Only one case had concomitant SCC [11]. In three reports there was accompanying actinic keratosis, the authors presumed that the

| Patient | Age (years) | Localization | Size (cm) | Type of burn | Actinic damage | Latent period (years) | Duration of complaints | Simultaneous neoplasm | Follow-up metastasis or other cancers |
|---------|-------------|--------------|-----------|--------------|----------------|----------------------|-----------------------|----------------------|-------------------------------------|
| Eckert et al. [11] | 66/M | The left side of his face | Not recorded | Thermal burn | Present | >50 | Not recorded | SCC | Not recorded |
| Hiscutt et al. [10] | 50/M | The angle of the mandibular | 1.3 × 1.2 cm | Flame burn | Present | 47 | 2 months | No | 10 years later he presented with SCC and MM |
| Ergüün et al. [13] | 66/M | Left cheek | 4.2 × 2.3 cm | Flame burn | Present | 65 | 8 months | No | No |
| Ito et al. [12] | 93/M | Left upper back | 3.5 × 2.7 cm | Moxa-cauterity | Not observed | Not recorded | 1 year | No | No |
| Current case | 31/M | Mid back | 1.3 cm and 0.5 cm | Thermal burn | Not observed | 20 | 6 months | No | No |

Table 1: Review of the reported cases and the current case. Moxa cauterity represents a Japanese folk remedy that is believed to relieve several symptoms, including pain.

References

1. Brenn T (2014) Pleomorphic dermal neoplasms: A review. Adv Anat Pathol 21: 108-130.

2. Koch M, Freundl AJ, Agaimy A, Kiesewetter F, Kuenzel J, et al. (2015) Atypical fibroxanthoma-histological diagnosis, immunohistochemical markers and concepts of therapy. Anticancer Res 35: 5717-5735.

3. Shahabi N, Galor A, Dubovy SR, Thompson J, Bermudez-Magner JA, et al. (2015) Atypical Fibroxanthoma of the Conjunctiva in Xeroderma Pigmentosum. Ocul Oncol Pathol 21: 108-130.

4. Lee SM, Zhang W, Fernandez MP (2014) Atypical Fibroxanthoma arising in a young patient with Li-Fraumeni syndrome. J Cutan Pathol 41: 303.

5. Kowal-Vern A, Crisswell BK (2005) Burn scar neoplasms: A literature review and statistical analysis. Burns 31: 403-413.

6. Lopez L, Veliz R (2016) Atypical fibroxanthoma. Arch Pathol Lab Med 140: 376.

7. Mellemkjaer L, Holmich LR, Gridley G, Rakkin C, Olsen JH (2006) Risks for skin and other cancers up to 25 years after burn injuries. Epidemiology 17: 668-673.

8. Bostwick J, Pendergast WJ, Vasconez LO (1976) Marjolin’s ulcer: An immunologically privileged tumor? Plast Reconstr Surg 57: 66-69.

9. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1657.

10. Hiscutt EL, Adams JR, Ryan JM, Langtry JA, Natarajan S (2009) Atypical fibroxanthoma, lentigo maligna melanoma and squamous cell carcinoma arising in the site of a thermal burn treated with skin grafts. Br J Oral Maxillofac Surg 47: 157.

11. Eckert F, Schaich B, Landthaler M (1991) Spinal cord tumors on the skin. J Neurol 238: 54-59.

12. Ito A, Yamada N, Yoshida Y, Morino S, Yamamoto O (2011) Myofibroblastic differentiation in atypical fibroxanthomas occurring on sun-exposed skin and in a burn scar: An ultrastructural and immunohistochemical study. J Cutan Pathol 38: 670.

13. Ergüün SS, BÜyÜkbabani N, Su O (2011) Atypical fibroxanthoma in a chronic burn scar of the cheek. J Dermatol 38: 1000-1003.